Residents Demand Answers at Council Meeting on Police Killing of Sayed Faisal


Bob Odenkirk Named Hasty Pudding Man of the Year


Harvard Kennedy School Dean Reverses Course, Will Name Ken Roth Fellow


Ex-Provost, Harvard Corporation Member Will Investigate Stanford President’s Scientific Misconduct Allegations


Harvard Medical School Drops Out of U.S. News Rankings

Harvard Law School Launches First-Ever Research Initiative on Psychedelics and the Law

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School studies the law and policy around health care.
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School studies the law and policy around health care. By Truong L. Nguyen
By Emmy M. Cho, Crimson Staff Writer

Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics is launching a first-of-its-kind research initiative focused on psychedelics and the law, the center announced Wednesday.

Titled the Project on Psychedelics Law and Regulation, the three-year project will “promote safety, innovation, equity, and access” in both psychedelic research and treatment, according to a press release.

“POPLAR is the first academic initiative focused on psychedelics law and policy, positioned to be the global leader for research and education in this space,” the release reads.

Mason M. Marks, senior fellow at the Petrie-Flom Center and project lead for POPLAR, said in an interview that the Petrie-Flom Center — an institution at the “cutting edge of health care policy and technology” — was the “perfect place” to pursue the initiative.

“Psychedelics are one of the most exciting and promising new technologies in mental health care to come along for decades, and they could represent a true paradigm shift for mental health care and neuroscience research in general,” Marks said. “That’s why the Petrie-Flom Center is such a great place to house the project.”

According to the project website, POPLAR will focus on areas including ethics in psychedelics research and treatment, the intersection of psychedelics and intellectual property law, federal support of psychedelics research, increased access and equity of psychedelics, and the function of psychedelics in mitigating trauma.

Others who are helping lead the project include Petrie-Flom Center Faculty Director I. Glenn Cohen, Law School professor Jeannie Suk Gersen, and Petrie-Flom Center Executive Director Carmel Shachar.

Despite the increased academic interest around psychedelics, Marks — who previously taught at the Gonzaga University School of Law and is an incoming assistant professor at the University of New Hampshire — said all of the research programs at institutions including Harvard, Johns Hopkins, Yale, and New York University were medically-oriented.

“There’s really nothing that’s focused on law and policy, so I saw that as a real gap,” Marks said. “You can advance the science as much as you want, but unless you change the law and the regulation, you’re still going to be constrained by these outdated policies from the 1970s that have been effectively hamstringing psychedelics research for half a century.”

Though federal law concerning psychedelics has largely remained the same since decades ago, Marks said that on the state and local level, there has been “a lot of activity.”

“There are seven U.S. cities that have decriminalized psychedelics,” Marks said. “Three of them are in Massachusetts — Somerville, Cambridge, and North Hampton. Massachusetts is really in a lot of ways on the cutting edge, and there’s some talk about potentially decriminalizing at the state level.”

POPLAR is funded by the Saisei Foundation, a charitable organization led by author and entrepreneur Tim Ferriss.

—Staff writer Emmy M. Cho can be reached at

Want to keep up with breaking news? Subscribe to our email newsletter.

HealthHarvard Law SchoolResearchMental Health